Reuters logo
BRIEF-Novartis Pharmaceuticals Canada says combination treatment tafinlar plus mekinist approved by Health Canada
June 15, 2017 / 12:10 PM / 5 months ago

BRIEF-Novartis Pharmaceuticals Canada says combination treatment tafinlar plus mekinist approved by Health Canada

June 15 (Reuters) - Novartis Ag

* Novartis Pharmaceuticals Canada - combination treatment tafinlar plus mekinist approved by Health Canada to treat braf V600-positive metastatic NSCLC after prior systemic therapy Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below